Physician profile
Ty Comer
NPI 1831805209
$2,860.64
in general payments reported to CMS, 2019-2025
32 companies · $704 in 2025
The $704 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,304 · 2024: $853 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793 · Education: $48.84 · Entertainment: $18.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.04 |
| Education | $48.84 |
| Entertainment | $18.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $356.43 | 2023-2024 | Caplyta |
| Novo Nordisk INC | $284.77 | 2024-2025 | Ozempic, Wegovy |
| Corium, LLC | $241.95 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $161.69 | 2023-2025 | Rexulti, Abilify Mycite |
| Tris Pharma INC | $153.98 | 2023-2024 | Dyanavel Xr |
| Shield Therapeutics INC | $151.94 | 2024 | |
| Abbvie INC. | $148.06 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.52 | 2023-2024 | Trintellix |
| Exact Sciences Corporation | $118.73 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $112.07 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $99.53 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $92.19 | 2023 | Hetlioz, Fanapt |
| Pfizer INC. | $68.22 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $66.57 | 2024-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $60.99 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $59.84 | 2024 | Impella |
| Lilly USA, LLC | $58.95 | 2024-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $58.87 | 2023-2024 | Austedo Xr |
| Alkermes, INC. | $54.00 | 2023 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $50.40 | 2023-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $49.60 | 2023 | Jornay Pm |
| Inspire Medical Systems, INC. | $42.47 | 2025 | Inspire |
| Hologic Sales and Service, LLC | $36.40 | 2025 | Aptima |
| Glaxosmithkline, LLC. | $35.47 | 2025 | Arexvy, Shingrix |
| Alk-Abello, INC | $29.65 | 2025 | Grastek, Ragwitek, Odactra |
| Dexcom, INC. | $23.65 | 2025 | Dexcom G6 Transmitter |
| Noven Therapeutics, LLC | $23.38 | 2024 | Xelstrym, Secuado |
| Philips North America LLC | $21.93 | 2024 | (Ck6) Holter |
| Tms Neurohealth Centers INC. | $19.20 | 2025 | Tms Neurohealth Centers INC. |
| Optos, INC. | $18.76 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Neos Therapeutics, Lp | $16.45 | 2023 | Adzenys Xr-Odt |
| Currax Pharmaceuticals LLC | $14.98 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ty Comer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.